UnknownPhase 2NCT04023149
Efficacy of Interleukin-2 Gargle in the Treatment of Oral Mucosa Lesion in Pemphigus Vulgaris
Studying Pemphigus vulgaris
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Second Xiangya Hospital of Central South University
- Principal Investigator
- Qianjin LuCentral South University
- Intervention
- recombinant human interleukin-2 (rhIL-2)(drug)
- Enrollment
- 180 target
- Eligibility
- 18-70 years · All sexes
- Timeline
- 2020 – 2021
Study locations (1)
- The Second Xiangya Hospital of Central South University, Changsha, Hunan, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04023149 on ClinicalTrials.govOther trials for Pemphigus vulgaris
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07384221Periodontal Status and Disease Severity in Pemphigus Vulgaris PatientsSaglik Bilimleri Universitesi
- RECRUITINGPHASE1, PHASE2NCT04422912A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)Cabaletta Bio
- RECRUITINGNCT02753777Autoimmune Blistering Diseases StudyUniversity of Pennsylvania